CN107043408B - 抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法 - Google Patents
抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法 Download PDFInfo
- Publication number
- CN107043408B CN107043408B CN201710198133.8A CN201710198133A CN107043408B CN 107043408 B CN107043408 B CN 107043408B CN 201710198133 A CN201710198133 A CN 201710198133A CN 107043408 B CN107043408 B CN 107043408B
- Authority
- CN
- China
- Prior art keywords
- antigen
- particle
- particles
- domain
- domain monomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002245 particle Substances 0.000 title claims abstract description 413
- 239000000178 monomer Substances 0.000 title claims abstract description 146
- 238000000034 method Methods 0.000 title abstract description 36
- 239000000539 dimer Substances 0.000 title description 69
- 239000000427 antigen Substances 0.000 claims abstract description 167
- 108091007433 antigens Proteins 0.000 claims abstract description 167
- 102000036639 antigens Human genes 0.000 claims abstract description 167
- 241001263478 Norovirus Species 0.000 claims abstract description 147
- 241000702670 Rotavirus Species 0.000 claims abstract description 116
- 229960005486 vaccine Drugs 0.000 claims abstract description 83
- 239000013598 vector Substances 0.000 claims abstract description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 67
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 52
- 102000004169 proteins and genes Human genes 0.000 claims description 41
- 235000018102 proteins Nutrition 0.000 claims description 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 23
- 230000028993 immune response Effects 0.000 claims description 22
- 235000001014 amino acid Nutrition 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 20
- 230000003612 virological effect Effects 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 19
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 18
- 239000003446 ligand Substances 0.000 claims description 18
- 235000018417 cysteine Nutrition 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 14
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 13
- 238000012377 drug delivery Methods 0.000 claims description 10
- 210000000056 organ Anatomy 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- 230000009977 dual effect Effects 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 2
- 239000006277 exogenous ligand Substances 0.000 claims 2
- 230000003053 immunization Effects 0.000 abstract description 30
- 238000002649 immunization Methods 0.000 abstract description 28
- 241000700605 Viruses Species 0.000 abstract description 27
- 238000003780 insertion Methods 0.000 abstract description 27
- 230000037431 insertion Effects 0.000 abstract description 27
- 208000015181 infectious disease Diseases 0.000 abstract description 23
- 108090000565 Capsid Proteins Proteins 0.000 abstract description 16
- 102100023321 Ceruloplasmin Human genes 0.000 abstract description 16
- 238000011161 development Methods 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 230000002458 infectious effect Effects 0.000 abstract description 6
- 238000010369 molecular cloning Methods 0.000 abstract description 3
- 230000002924 anti-infective effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000027455 binding Effects 0.000 description 51
- 238000010367 cloning Methods 0.000 description 47
- 241000699670 Mus sp. Species 0.000 description 46
- 108020003175 receptors Proteins 0.000 description 38
- 102000005962 receptors Human genes 0.000 description 38
- 241000699666 Mus <mouse, genus> Species 0.000 description 35
- 210000002966 serum Anatomy 0.000 description 32
- 230000015572 biosynthetic process Effects 0.000 description 25
- 102000005720 Glutathione transferase Human genes 0.000 description 21
- 108010070675 Glutathione transferase Proteins 0.000 description 21
- 230000000903 blocking effect Effects 0.000 description 20
- 210000000234 capsid Anatomy 0.000 description 18
- 238000006386 neutralization reaction Methods 0.000 description 17
- 239000013078 crystal Substances 0.000 description 16
- 239000011347 resin Substances 0.000 description 15
- 229920005989 resin Polymers 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 241000588724 Escherichia coli Species 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 230000003472 neutralizing effect Effects 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 239000002671 adjuvant Substances 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 244000052769 pathogen Species 0.000 description 12
- 101710132601 Capsid protein Proteins 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 230000030741 antigen processing and presentation Effects 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 108020001507 fusion proteins Proteins 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 238000002523 gelfiltration Methods 0.000 description 11
- 238000002741 site-directed mutagenesis Methods 0.000 description 11
- 241000714209 Norwalk virus Species 0.000 description 10
- 108090000190 Thrombin Proteins 0.000 description 10
- 238000001493 electron microscopy Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 108700021730 rotavirus NS35 Proteins 0.000 description 10
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
- 229960004072 thrombin Drugs 0.000 description 10
- 239000008280 blood Substances 0.000 description 9
- 238000001784 detoxification Methods 0.000 description 9
- 238000001641 gel filtration chromatography Methods 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000002163 immunogen Effects 0.000 description 8
- 210000003296 saliva Anatomy 0.000 description 8
- 241001135960 Murine rotavirus Species 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 208000005577 Gastroenteritis Diseases 0.000 description 6
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 6
- 108010067390 Viral Proteins Proteins 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000005090 green fluorescent protein Substances 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- 229940031626 subunit vaccine Drugs 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 5
- 241000723655 Cowpea mosaic virus Species 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 235000013861 fat-free Nutrition 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000011725 BALB/c mouse Methods 0.000 description 4
- 241000193738 Bacillus anthracis Species 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 241000617996 Human rotavirus Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241000204666 Thermotoga maritima Species 0.000 description 4
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 4
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000000521 hyperimmunizing effect Effects 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 3
- 101000802660 Homo sapiens Histo-blood group ABO system transferase Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 241000701029 Murid betaherpesvirus 1 Species 0.000 description 3
- 208000031662 Noncommunicable disease Diseases 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108070000030 Viral receptors Proteins 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000003113 dilution method Methods 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 150000002482 oligosaccharides Polymers 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XMTQQYYKAHVGBJ-UHFFFAOYSA-N 3-(3,4-DICHLOROPHENYL)-1,1-DIMETHYLUREA Chemical compound CN(C)C(=O)NC1=CC=C(Cl)C(Cl)=C1 XMTQQYYKAHVGBJ-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102100022749 Aminopeptidase N Human genes 0.000 description 2
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- OZIOWHWTZWIMCZ-MPUPURDASA-N B-Trisaccharide Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 OZIOWHWTZWIMCZ-MPUPURDASA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000589969 Borreliella burgdorferi Species 0.000 description 2
- 241000714198 Caliciviridae Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 2
- 101150066516 GST gene Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 108091006054 His-tagged proteins Proteins 0.000 description 2
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 2
- 241000369774 Norwalk-like virus Species 0.000 description 2
- 102100034574 P protein Human genes 0.000 description 2
- 101710181008 P protein Proteins 0.000 description 2
- 108091081548 Palindromic sequence Proteins 0.000 description 2
- 101710177166 Phosphoprotein Proteins 0.000 description 2
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 208000012873 acute gastroenteritis Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002434 immunopotentiative effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 244000052613 viral pathogen Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- AEGSIYIIMVBZQU-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1r)-1-carboxy-2-sulfanylethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(O)=O AEGSIYIIMVBZQU-CIUDSAMLSA-N 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- UQBGYPFHWFZMCD-ZLUOBGJFSA-N Asp-Asn-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O UQBGYPFHWFZMCD-ZLUOBGJFSA-N 0.000 description 1
- JUWZKMBALYLZCK-WHFBIAKZSA-N Asp-Gly-Asn Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O JUWZKMBALYLZCK-WHFBIAKZSA-N 0.000 description 1
- 101001086191 Borrelia burgdorferi Outer surface protein A Proteins 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 208000006339 Caliciviridae Infections Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000867607 Chlorocebus sabaeus Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- OIMUAKUQOUEPCZ-WHFBIAKZSA-N Cys-Asn-Gly Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIMUAKUQOUEPCZ-WHFBIAKZSA-N 0.000 description 1
- OLIYIKRCOZBFCW-ZLUOBGJFSA-N Cys-Asp-Cys Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CS)N)C(=O)O OLIYIKRCOZBFCW-ZLUOBGJFSA-N 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- LVCHEMOPBORRLB-DCAQKATOSA-N Glu-Gln-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCC(O)=O)C(O)=O LVCHEMOPBORRLB-DCAQKATOSA-N 0.000 description 1
- NKLRYVLERDYDBI-FXQIFTODSA-N Glu-Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKLRYVLERDYDBI-FXQIFTODSA-N 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- AQCUAZTZSPQJFF-ZKWXMUAHSA-N Ile-Ala-Gly Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O AQCUAZTZSPQJFF-ZKWXMUAHSA-N 0.000 description 1
- HRTRLSRYZZKPCO-BJDJZHNGSA-N Leu-Ile-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HRTRLSRYZZKPCO-BJDJZHNGSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241001223865 Murine rotavirus EDIM Species 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- 108010047562 NGR peptide Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229940124941 Rotarix Drugs 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 238000013308 adult mouse model Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 108010006195 arginyl-glycyl-aspartyl-cysteine Proteins 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000012866 crystallographic experiment Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 244000078673 foodborn pathogen Species 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 102000056538 human ABO Human genes 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- -1 isopropyl- Chemical group 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000002062 molecular scaffold Substances 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 230000001002 morphogenetic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- FLZWAAFMRTZQGV-ULZIYQADSA-N n-[(2r,3r,4r,5r,6r)-4,5-dihydroxy-6-(hydroxymethyl)-2-[(2r,3s,4s,5r)-4,5,6-trihydroxy-1-oxo-2-[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyhexan-3-yl]oxyoxan-3-yl]acetamide Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H](C=O)[C@H]([C@@H](O)[C@H](O)CO)O[C@@H]1[C@H](NC(C)=O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 FLZWAAFMRTZQGV-ULZIYQADSA-N 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000006394 virus-host interaction Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/16011—Caliciviridae
- C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18556409P | 2009-06-09 | 2009-06-09 | |
| US61/185,564 | 2009-06-09 | ||
| US22469609P | 2009-07-10 | 2009-07-10 | |
| US61/224,696 | 2009-07-10 | ||
| CN2010800353022A CN102612525A (zh) | 2009-06-09 | 2010-06-09 | 抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800353022A Division CN102612525A (zh) | 2009-06-09 | 2010-06-09 | 抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107043408A CN107043408A (zh) | 2017-08-15 |
| CN107043408B true CN107043408B (zh) | 2021-02-09 |
Family
ID=43309459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710198133.8A Active CN107043408B (zh) | 2009-06-09 | 2010-06-09 | 抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法 |
| CN2010800353022A Pending CN102612525A (zh) | 2009-06-09 | 2010-06-09 | 抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800353022A Pending CN102612525A (zh) | 2009-06-09 | 2010-06-09 | 抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8486421B2 (https=) |
| EP (1) | EP2440582B1 (https=) |
| JP (1) | JP5894528B2 (https=) |
| CN (2) | CN107043408B (https=) |
| WO (1) | WO2010144602A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8486421B2 (en) | 2009-06-09 | 2013-07-16 | Children's Hospital Medical Center | Antigen-norovirus P-domain monomers and dimers, antigen-norovirus P-particle molecules, and methods for their making and use |
| CA2787666A1 (en) * | 2010-01-21 | 2011-07-28 | Ligocyte Pharmaceuticals, Inc. | Targeted heterologous antigen presentation on calicivirus virus-like particles |
| FI122520B (fi) * | 2010-10-15 | 2012-03-15 | Vesna Blazevic | Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena |
| US9562077B2 (en) * | 2012-07-11 | 2017-02-07 | Children's Hospital Medical Center | Protein complex system for increased immunogenicity and functionality, and methods making and use |
| CN103304642B (zh) * | 2013-06-06 | 2015-01-07 | 黑龙江八一农垦大学 | 猪轮状病毒δvp8*亚单位重组蛋白及其应用 |
| US9321803B2 (en) | 2013-07-12 | 2016-04-26 | Children's Hospital Medical Center | Compositions and methods for inhibiting norovirus infection |
| CN107034198B (zh) * | 2015-07-15 | 2021-03-09 | 长春百克生物科技股份公司 | 一种嵌合诺如病毒p颗粒及其制备和应用 |
| CN106220738A (zh) * | 2016-07-31 | 2016-12-14 | 中国医学科学院医学生物学研究所 | Ev71中和抗原表位与诺如病毒p结构域嵌合载体的构建和表达方法 |
| EP3600397A4 (en) | 2017-03-28 | 2021-01-27 | Children's Hospital Medical Center | NOROVIRUS PARTICLE VACCINES AND THEIR MANUFACTURING AND USE PROCEDURES |
| WO2020014654A1 (en) * | 2018-07-13 | 2020-01-16 | The Trustees Of Indiana University | Recombinant rotavirus expression system and recombinant rotaviruses |
| JP7190674B2 (ja) * | 2018-08-23 | 2022-12-16 | パナソニックＩｐマネジメント株式会社 | ノロウイルスに結合する抗体、複合体、それを用いた検出装置及び検出方法 |
| WO2021140524A1 (en) * | 2020-01-08 | 2021-07-15 | Bharat Biotech International Limited | Viral vaccine compositions and methods of preparations thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006138514A2 (en) * | 2005-06-16 | 2006-12-28 | Children's Hospital Medical Center | Novel norovirus particle for use as an antiviral or vaccine |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4550019A (en) | 1978-03-22 | 1985-10-29 | South Africa Inventions Development Corporation | Manufacture and use of fowl egg antibodies |
| US4769238A (en) * | 1981-08-04 | 1988-09-06 | The Regents Of The University Of California | Synthesis of human virus antigens by yeast |
| US4916213A (en) | 1983-02-22 | 1990-04-10 | Xoma Corporation | Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof |
| US4547367A (en) * | 1983-12-20 | 1985-10-15 | The United States Of America As Represented By The Department Of Health And Human Services | Hepatitis B core antigen vaccine |
| US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
| US5338689A (en) | 1987-08-24 | 1994-08-16 | Stiftung Fur Diagnostische Forschung | Method and card for detecting antigens and/or antibodies |
| ZA896668B (en) | 1988-09-01 | 1990-06-27 | Molecular Therapeutics Inc | A human rhinovirus receptor protein that inhibits virus infectivity |
| US5068191A (en) | 1989-08-31 | 1991-11-26 | The Biomembrane Institute | Purified histo-blood group a glycosyltransferase and antibodies thereto |
| JP3310281B2 (ja) * | 1989-11-08 | 2002-08-05 | ベイラー カレッジ オブ メディシン | ノーワーク及び関連のウィルスを検出し同定するための方法と試薬 |
| US6572862B1 (en) * | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
| CA2029219A1 (en) * | 1989-11-08 | 1991-05-09 | Mary K. Estes | Methods and reagents to detect and characterize norwalk and related viruses |
| FR2677767B1 (fr) | 1991-06-11 | 1994-10-14 | Biotechnologie Ste Europeenne | Procede de detection de l'infection par le virus de la diarrhee bovine, sequence nucleotidique codant pour une proteine induite par l'infection par ce virus et proteines et antigenes recombinants s'y rapportant . |
| DK0590060T3 (da) | 1991-06-21 | 1998-05-11 | Univ Cincinnati | Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| WO1993019660A1 (en) | 1992-04-03 | 1993-10-14 | Baylor College Of Medicine | Gene therapy using the intestine |
| US5374532A (en) | 1992-08-31 | 1994-12-20 | The Biomembrane Institute | Method for determining susceptibility to escherichia coli urinary tract infections and method for diagnosing secretors and nonsecretors |
| US5367054A (en) | 1993-04-12 | 1994-11-22 | Stolle Research & Development Corp. | Large-scale purification of egg immunoglobulin |
| DE4335025A1 (de) | 1993-10-14 | 1995-04-20 | Boehringer Ingelheim Int | Endosomolytisch wirksame Partikel |
| US5750394A (en) | 1994-05-20 | 1998-05-12 | The Mount Sinai Medical Center | Identification and use of antiviral compounds that inhibit interaction of host cell proteins and viral proteins required for viral replication |
| US6300090B1 (en) | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
| US5861241A (en) * | 1995-08-16 | 1999-01-19 | University Of Massachusetts | Monoclonal antibodies for detecting Norwalk virus |
| EP0845995A1 (en) | 1995-08-18 | 1998-06-10 | Dr. Rentschler Biotechnologie GmbH | Pharmaceutical compositions for competitively inhibiting the binding of a retrovirus to the ifn-receptor and means for diagnosis of an hiv infection |
| US5891862A (en) | 1996-03-15 | 1999-04-06 | Geltex Pharmaceuticals, Inc. | Polyvalent polymers for the treatment of rotavirus infection |
| IL118625A0 (en) | 1996-06-11 | 1996-10-16 | Xtl Biopharmaceuticals Limited | Anti HBV antibodies |
| US6225290B1 (en) | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
| US6045854A (en) | 1997-03-31 | 2000-04-04 | Abbott Laboraties | Nutritional formulations containing oligosaccharides |
| US20020019991A1 (en) | 1998-04-30 | 2002-02-14 | Abbott Laboratories | Compositions containing an alpha 1,2-fucose linkage and uses thereof |
| US6593080B1 (en) * | 1999-02-01 | 2003-07-15 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Diagnosis, prevention and treatment of calicivirus infection in humans |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| CN1330080A (zh) * | 2000-06-19 | 2002-01-09 | 上海博德基因开发有限公司 | 一种新的多肽——人含p结构域的蛋白10和编码这种多肽的多核苷酸 |
| US6946266B2 (en) | 2000-12-20 | 2005-09-20 | Fred Hutchinson Cancer Research Center | Gene transfer in chicken bursal stem cells |
| JP2004534088A (ja) | 2001-07-06 | 2004-11-11 | スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ | 癌のための多価コンジュゲートワクチン |
| US7977098B2 (en) * | 2002-05-31 | 2011-07-12 | Children's Hospital Medical Center | Antigenic binding patterns of norovirus to human histo-blood group antigens |
| WO2003101176A2 (en) | 2002-05-31 | 2003-12-11 | Children's Hospital Medical Center | Method, composition and kit for antigenic binding of norwalk-like viruses |
| US7785871B2 (en) * | 2002-10-09 | 2010-08-31 | Intrexon Corporation | DNA cloning vector plasmids and methods for their use |
| US20080050808A1 (en) | 2002-10-09 | 2008-02-28 | Reed Thomas D | DNA modular cloning vector plasmids and methods for their use |
| EP1642475B1 (en) | 2003-07-03 | 2015-08-26 | Sung-Chul Sohn | System and method for zone-based personalized information providing |
| US20070280949A1 (en) | 2003-07-10 | 2007-12-06 | Michelle Alfa | Combination Therapy for Gastroenteric Diseases Caused by Microorganisms |
| WO2005032457A2 (en) | 2003-07-21 | 2005-04-14 | Boyce Thompson Institute For Plant Research, Inc. | Vectors and methods for immunization against norwalk virus using transgenic plants |
| JP2007537137A (ja) * | 2003-09-24 | 2007-12-20 | モンタナ ステート ユニバーシティ | ノロウィルスモノクローナル抗体及びペプチド |
| US20070231320A1 (en) | 2006-04-03 | 2007-10-04 | Cook Mark E | Eggs having increased antibody titer and methods for making same |
| US20110152263A1 (en) | 2006-11-16 | 2011-06-23 | Xi Jiang | Composition and method for inhibiting norovirus infection |
| US8475789B2 (en) | 2008-01-22 | 2013-07-02 | Multimerics Aps | Products and methods to prevent infections |
| ATE531570T1 (de) | 2009-01-14 | 2011-11-15 | Magna Auteca Ag | Antrieb für ein zu verstellendes bauteil |
| US8486421B2 (en) | 2009-06-09 | 2013-07-16 | Children's Hospital Medical Center | Antigen-norovirus P-domain monomers and dimers, antigen-norovirus P-particle molecules, and methods for their making and use |
-
2010
- 2010-06-09 US US12/797,396 patent/US8486421B2/en active Active
- 2010-06-09 CN CN201710198133.8A patent/CN107043408B/zh active Active
- 2010-06-09 JP JP2012515109A patent/JP5894528B2/ja active Active
- 2010-06-09 WO PCT/US2010/038008 patent/WO2010144602A2/en not_active Ceased
- 2010-06-09 CN CN2010800353022A patent/CN102612525A/zh active Pending
- 2010-06-09 EP EP10786797.0A patent/EP2440582B1/en active Active
-
2013
- 2013-06-24 US US13/924,906 patent/US9096644B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006138514A2 (en) * | 2005-06-16 | 2006-12-28 | Children's Hospital Medical Center | Novel norovirus particle for use as an antiviral or vaccine |
Non-Patent Citations (1)
| Title |
|---|
| Chimeric calicivirus-like particles elicit protective anti-viral cytotoxic responses without adjuvant;E. Crisci等;《Virology》;20090326;第387卷;第303–312页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US9096644B2 (en) | 2015-08-04 |
| WO2010144602A2 (en) | 2010-12-16 |
| WO2010144602A3 (en) | 2011-05-19 |
| EP2440582A2 (en) | 2012-04-18 |
| JP5894528B2 (ja) | 2016-03-30 |
| US8486421B2 (en) | 2013-07-16 |
| US20130273090A1 (en) | 2013-10-17 |
| CN107043408A (zh) | 2017-08-15 |
| EP2440582B1 (en) | 2018-11-07 |
| JP2012529298A (ja) | 2012-11-22 |
| CN102612525A (zh) | 2012-07-25 |
| EP2440582A4 (en) | 2013-01-30 |
| US20100322962A1 (en) | 2010-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107043408B (zh) | 抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法 | |
| ES2248791T3 (es) | Proteina de capsidas del virus del papiloma hpv1 recombinantes que se autoensamblan. | |
| Xia et al. | Norovirus capsid protein expressed in yeast forms virus‐like particles and stimulates systemic and mucosal immunity in mice following an oral administration of raw yeast extracts | |
| US6589529B1 (en) | Rotavirus subunit vaccine | |
| KR101624358B1 (ko) | 고리스크군 인간 파필로마 바이러스에 대한 교차성 중화 항체를 유도하는 백신 항원 | |
| US6485728B2 (en) | Formalin-Inactivated human papillomavirus L1 protein vaccine | |
| US6165471A (en) | Homogeneous human papillomavirus capsomere containing compositions, methods for manufacture, and use thereof as diagnostic, prophylactic or therapeutic agents | |
| TW202229314A (zh) | 用於針對輪狀病毒疫苗接種之融合蛋白質 | |
| Huo et al. | Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice | |
| CA2329136A1 (en) | Oral immunization with papillomavirus virus-like particles | |
| Kovacs-Nolan et al. | Tandem copies of a human rotavirus VP8 epitope can induce specific neutralizing antibodies in BALB/c mice | |
| CA2295316C (en) | Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy | |
| CN105085671B (zh) | 抗肠道病毒3d蛋白的单克隆免疫球蛋白g抗体及其免疫原性组合物 | |
| CN119894528A (zh) | 用于针对轮状病毒疫苗接种的免疫原性组合物 | |
| WO2011136506A9 (ko) | 로타바이러스 나노입자를 이용한 재조합 복합 항원의 제조방법 | |
| HK1169426B (en) | Antigen-norovirus p-domain monomers and dimers, antigen-norovirus p-particle molecules, and methods for their making and use | |
| HK1169426A (en) | Antigen-norovirus p-domain monomers and dimers, antigen-norovirus p-particle molecules, and methods for their making and use | |
| Lyu et al. | Achievements, challenges and prospects for the development of broadly protective multivalent vaccines and therapeutic antibodies against hand, foot and mouth disease | |
| AU2004203804B2 (en) | Rotavirus subunit vaccine | |
| Johnson | Umesh Katpally and Thomas J. Smith | |
| Neutralizing et al. | Chimeric Virus-Like Particle Vaccines | |
| Embers | Immunogenicity and Cellular Protein Associations of the Papillomavirus Minor Capsid Protein | |
| Kamstrup et al. | The plant as a factory for the production of oral vaccines | |
| Quek | Epitope mapping of the non-structural protein 2 (NSP2) of rotavirus | |
| Entry | Cross-Linking of Rotavirus Outer Capsid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |